Erytech Pharma SA has reported Phase 2 data for a new formulation of asparaginase, in combination with chemotherapy, showing the drug was safe and effective in older patients with acute lymphoblastic leukaemia (ALL) for whom no alternatives exist. ---Subscribe to MedNous to access this article--- Clinical Research Company News
